Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $20.4 million.

  • Zevra Therapeutics' Operating Expenses fell 2499.17% to $20.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.9 million, marking a year-over-year decrease of 679.96%. This contributed to the annual value of $97.0 million for FY2024, which is 3081.89% up from last year.
  • Latest data reveals that Zevra Therapeutics reported Operating Expenses of $20.4 million as of Q3 2025, which was down 2499.17% from $24.2 million recorded in Q2 2025.
  • In the past 5 years, Zevra Therapeutics' Operating Expenses registered a high of $27.2 million during Q3 2024, and its lowest value of $4.2 million during Q3 2021.
  • Moreover, its 5-year median value for Operating Expenses was $18.1 million (2023), whereas its average is $16.4 million.
  • In the last 5 years, Zevra Therapeutics' Operating Expenses surged by 32364.7% in 2022 and then tumbled by 4611.96% in 2023.
  • Quarter analysis of 5 years shows Zevra Therapeutics' Operating Expenses stood at $5.4 million in 2021, then surged by 108.98% to $11.3 million in 2022, then surged by 130.07% to $26.1 million in 2023, then decreased by 6.14% to $24.5 million in 2024, then decreased by 16.79% to $20.4 million in 2025.
  • Its Operating Expenses stands at $20.4 million for Q3 2025, versus $24.2 million for Q2 2025 and $22.8 million for Q1 2025.